SSB
BEAM icon

Sandy Spring Bank’s Beam Therapeutics BEAM Stock Holding History

Sandy Spring Bank’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$17.6K Sell
900
-300
-25% -$7.86K ﹤0.01% 758
2024
Q4 		$29.8K Hold
1,200
– – ﹤0.01% 682
2024
Q3 		$29.4K Hold
1,200
– – ﹤0.01% 694
2024
Q2 		$28.1K Hold
1,200
– – ﹤0.01% 691
2024
Q1 		$39.6K Buy
+1,200
New +$37.4K ﹤0.01% 628

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sandy Spring Bank's BEAM Position: Q1 2025 in Review

Sandy Spring Bank reduced its Beam Therapeutics (BEAM) stake by 25% in Q1 2025, selling an estimated $7.86K and leaving 900 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #758.

Sandy Spring Bank first reported a position in BEAM in Q1 2024 and has held it in 5 quarters since. The position peaked at $39.6K in Q1 2024. 237 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

  • Sandy Spring Bank held 900 shares of Beam Therapeutics worth $17.6K as of Q1 2025.
  • Sandy Spring Bank sold 300 Beam Therapeutics shares in Q1 2025, an estimated $7.86K.
  • Beam Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #758 holding.
  • Sandy Spring Bank first reported a position in Beam Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Sandy Spring Bank's Beam Therapeutics position peaked at $39.6K in Q1 2024.
  • 237 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.